Publications by authors named "Mina Ying Min Wu"
Alpha-1-antitrypsin (A1AT) is a multifunctional, clinically important, high value therapeutic glycoprotein that can be used for the treatment of many diseases such as alpha-1-antitrypsin deficiency, diabetes, graft-versus-host-disease, cystic fibrosis and various viral infections. Currently, the only FDA-approved treatment for A1AT disorders is intravenous augmentation therapy with human plasma-derived A1AT. In addition to its limited supply, this approach poses a risk of infection transmission, since it uses therapeutic A1AT harvested from donors.
View Article and Find Full Text PDFArticle Synopsis
- Therapeutic proteins have been successful in treating various diseases, with glycosylation being a critical quality feature that affects their properties and effectiveness.
- Optimizing the glycosylation process can enhance the safety and efficacy of both existing and developing protein-based drugs.
- The review explores how glycan structure variations affect drug performance and discusses implications for advanced therapies like T cell-based cancer treatment and gene therapy.